Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis
- 1 December 2011
- journal article
- case report
- Published by Elsevier BV in Mayo Clinic Proceedings
- Vol. 86 (12), 1188-1191
- https://doi.org/10.4065/mcp.2011.0518
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling StudyJournal of Clinical Oncology, 2011
- How I treat myelofibrosisBlood, 2011
- Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in MyelofibrosisJournal of Clinical Oncology, 2011
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in MyelofibrosisNew England Journal of Medicine, 2010
- Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1Leukemia, 2010
- Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithmsLeukemia, 2007
- MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid MetaplasiaPLoS Medicine, 2006
- Pathogenesis of Myelofibrosis With Myeloid MetaplasiaJournal of Clinical Oncology, 2005
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- Myelofibrosis with Myeloid MetaplasiaThe New England Journal of Medicine, 2000